LAUSR

We read with great interest the recent article by Cheng et al. [1] in this journal. The authors presented a systematic review and meta-analysis of data comparing the effect of vonoprazan, a potassium-competitive acid blocker (P-CAB), and other ordinal proton pump inhibitors (PPIs). We would like to thank them for performing this systematic review and for including our original paper that assessed the effect of vonoprazan on the complete relief of heartburn in erosive esophagitis [2]. However, the conclusions and issues raised by Cheng et al. and our views on the publication differ. For example, the referred sample numbers and the risk-of-bias assessment might not be accurate or reasonable (Fig. 1a, b). Vonoprazan is now available in Japan, the Philippines, Singapore, Thailand and Malaysia. Another P-CAB, Tegoprazan, is also currently available in South Korea. P-CABs have rapid, stable, and long-lasting acid blocking effects, while ordinal PPIs require 3–5 days in order to achieve maximal and steady-state inhibition of acid secretion [3, 4]. Furthermore, the advantage of